Drug intelligence / Profile preview

HCI-1401

Development stage: Preclinical
Lead developer: Elevar Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

HCI-1401 is an orally bioavailable, small-molecule, irreversible inhibitor of Bruton's tyrosine kinase (BTK) being developed primarily for the treatment of B‑cell malignancies and potentially autoimmune diseases. It was discovered at Huntsman Cancer Institute and exclusively licensed to LSK BioPharma (now Elevar Therapeutics) for further development and commercialization worldwide.[1][7][8][10] Preclinical in vitro data indicate that HCI-1401 is several-fold more potent against BTK than first-generation BTK inhibitors, with the goal of providing deeper and more durable B‑cell pathway inhibition while retaining a favorable safety profile for chronic administration.[1][8][10]

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on HCI-1401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCI-1401.

Explore the full profile